4:41 PM ET
8-K
M&A Deal
Rallybio M&A Deal with Avenzo Therapeutics, Inc.
Rallybio Corp announced that its pending merger with Avenzo Therapeutics is expected to close following the close of trading on November 20, 2026. The company also provided a timeline update for its previously announced special cash distribution of $13.90 per share, which will be paid to stockholders of record as of November 5, 2026, following Nasdaq due bill procedures.
- Counterparty
- Avenzo Therapeutics, Inc.